The aim of this study was to determine if administration of intra-arterial carboplatin (IAC) affected the hearing of children being treated for retinoblastoma. This was a prospective study in which 22 of 40 consented children completed therapy. Hearing was tested pretreatment start and at three- and nine-months post treatment completion. >10dB change from baseline was classed as hearing loss on audiogram measurement or on distortion product otoacoustic emission assessment. Mean age was 16 months (range two months to 4.5 years). There was no significant difference in measurements pre to post treatment for hearing testing for all participants. The authors conclude hearing loss was not associated with IAC. They acknowledge their small sample size and recommend further continued observations for effects of IAC therapy.
Intra-arterial carboplatin therapy not associated with hearing loss
Reviewed by Fiona Rowe
Hearing evaluations in children with retinoblastoma with intra-arterial carboplatin chemotherapy: a single institution review.
CONTRIBUTOR
Fiona Rowe (Prof)
Institute of Population Health, University of Liverpool, UK.
View Full Profile
